Pfizer Inc. (NYSE:PFE) Shares Sold by Hoertkorn Richard Charles

Hoertkorn Richard Charles cut its position in Pfizer Inc. (NYSE:PFE) by 9.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,337 shares of the biopharmaceutical company’s stock after selling 572 shares during the quarter. Hoertkorn Richard Charles’ holdings in Pfizer were worth $142,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. United Bank lifted its stake in shares of Pfizer by 3.7% in the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock worth $1,030,000 after acquiring an additional 1,277 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Pfizer by 67.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 14,801 shares of the biopharmaceutical company’s stock valued at $428,000 after purchasing an additional 5,959 shares in the last quarter. Loomis Sayles & Co. L P increased its position in shares of Pfizer by 7.3% during the 3rd quarter. Loomis Sayles & Co. L P now owns 8,450 shares of the biopharmaceutical company’s stock valued at $245,000 after purchasing an additional 577 shares during the period. FMR LLC lifted its holdings in shares of Pfizer by 3.1% in the third quarter. FMR LLC now owns 14,478,489 shares of the biopharmaceutical company’s stock valued at $419,007,000 after buying an additional 435,311 shares during the period. Finally, Quantbot Technologies LP bought a new position in Pfizer during the third quarter valued at about $1,685,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Activity

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is currently owned by insiders.

Pfizer Stock Performance

Shares of PFE stock opened at $25.05 on Friday. The firm has a market cap of $142.08 billion, a P/E ratio of 17.77, a PEG ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The stock’s 50-day moving average is $26.09 and its two-hundred day moving average is $26.97.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter last year, the firm earned $0.10 earnings per share. The company’s revenue for the quarter was up 24.7% on a year-over-year basis. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of research analyst reports. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup reduced their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Finally, Bank of America reaffirmed a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.